Anti-Platelet-activating factor acetylhydrolase (Lp-PLA2) antibody *Mouse anti-human, monoclonal IgG3*
Lipoprotein-associated phospholipase A2 (Lp-PLA2), or platelet-activating factor acetylhydrolase (PAF-AH), is a 45 kDa phospholipase enzyme produced by inflammatory cells such as mature macrophages and activated platelets. Lp-PLA2 is typically found present in the blood coupled to lipoproteins: 80% to LDL and 20% to HDL. It is essential for the hydrolysis of oxidized phospholipids, yielding pro-inflammatory lysophospholipids and oxidized fatty acids. In clinically biology, Lp-PLA2 is a significant biomarker associated with the development of atherosclerosis and cardiac disease. Anti-Lp-PLA2 monoclonal antibodies are highly specific for the detection of human Lp-PLA2 immunogens. They can be used for a broad range of immunoassays such as chemiluminescent immunoassay (CLIA), latex enhanced turbidimetric immunoassay (LETIA), ELISA and rapid sandwich immunoassays.
Conjugation
We provide custom conjugation services for this antibody (eg. labeling of Anti-Platelet-activating factor acetylhydrolase (Lp-PLA2) antibody *Mouse anti-human, monoclonal IgG3* with HRP). A list of available labels can be found in the table below:
For additional information about custom conjugations, please consult our services page here.
AF | AF350, AF488, AF555, AF594, AF647, AF680, AF700, AF750 |
Proteins | HRP, Alkaline Phosphatase, Streptavidin |
Tandems | APC, APC/Cy7, APC/AF750, APC/iFluor™ 700, APC/iFluor™ 750, PE, PE/Cy5, PE/Cy7, PE/AF610, PE/AF700, PE/iFluor™ 594, PE/iFluor™ 647, PE/iFluor™ 700, PE/iFluor™ 750, PE/Texas Red®, PerCP, PerCP/Cy5.5 |
Small Molecules | Biotin |
Traditional Dyes | FITC (fluorescein), TRITC, PacBlue, PacOrange, Cy3, Cy5 |
iFluor | 350, 405, 430, 450, 488, 514, 532, 546, 555, 560, 568, 594, 610, 633, 647, 660, 670, 680, 700, 710, 750, 790, 800, 810, 820, 840, 860, A7 |
mFluor | UV375, UV460, Violet 450, Violet 500, Violet 510, Violet 540, Blue 570, Green 620, Red 700, Red 780 |
For additional information about custom conjugations, please consult our services page here.
Page updated on November 19, 2024